DelveInsight
DelveInsight's primary conduit for delivering intelligent information to professionals in both the business and healthcare sectors is through its meticulously crafted analytical and strategic reports. Presently, DelveInsight boasts a diverse portfolio encompassing over 3,000 Marketed and Pipeline Reports. These reports are thoughtfully categorized based on parameters such as indication, mechanism of actions, drugs, global API manufacturers, and specialized reports focusing on pivotal areas such as Onco-Immunology, Orphan Diseases, Biologics & Biosimilars, Gene Therapy, Stem Cells Therapy, and other emerging domains. This robust platform has become the go-to resource for numerous enterprises seeking to transform and redefine their business strategies.
DelveInsight's offerings extend beyond reports to encompass Consulting Projects and Competitive Intelligence services, catering to the multifaceted needs of its clientele. Moreover, the organization is dedicated to providing tailor-made research services that align with the specific interests and requirements of its clients. DelveInsight's commitment to excellence and innovation positions it as a trusted partner in the areas of business strategy and market research.
View recent articles by this publisher on our blog:
4 Blockbuster Drugs to Watch for Non-Small Lung Cancer (NSCLC)
The Power of Digital Therapeutics in Mental Health
Anti-VEGF Therapies: Forever Market Rulers of Wet-AMD Treatment?
Additional articles from this publisher
10,954 Reports from DelveInsight
-
MPYS protein stimulants - Pipeline Insight, 2025
DelveInsight’s, “MPYS protein stimulants - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in MPYS protein stimulants pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers ... Read More
-
MPYS protein inhibitors - Pipeline Insight, 2025
DelveInsight’s, “MPYS protein inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in MPYS protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers th ... Read More
-
Protein tyrosine phosphatase non receptor type 11 antagonists - Pipeline Insight, 2025
DelveInsight’s, “Protein tyrosine phosphatase non receptor type 11 antagonists - Pipeline Insight, 2025” report provides comprehensive insights about 7+ companies and 8+ pipeline drugs in Protein tyrosine phosphatase non receptor type 11 antagonists pipeline landscape. It covers the pipeline drug pr ... Read More
-
Type II DNA topoisomerase inhibitors - Pipeline Insight, 2025
DelveInsight’s, “Type II DNA topoisomerase inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Type II DNA topoisomerase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage ... Read More
-
CDK12 Inhibitor- Pipeline Insight, 2025
DelveInsight’s, “CDK12 Inhibitor- Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in CDK12 Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics as ... Read More
-
RAGE Inhibitor - Pipeline Insight, 2025
DelveInsight’s, “RAGE Inhibitor - Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in RAGE Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics as ... Read More
-
HPK1 inhibitors - Pipeline Insight, 2025
DelveInsight’s, “HPK1 inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in HPK1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics ... Read More
-
Allergic Rhinitis - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the Allergic Rhinitis Market Size was highest in the US among the 7MM, accounting for approximately USD 3,600 million which is further expected to increase by 2034. In 2023, the prevalence of Allergic rhinitis was highest in Japan among the 7MM, accounting for approximately 6 ... Read More
-
Irritable Bowel Syndrome (IBS) - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights: Irritable bowel syndrome is believed to be a multifactorial disease involving motility dysfunction, visceral hypersensitivity, psychiatric comorbidity, neuroendocrine dysfunction, genetics and epigenetics, diet, and immune activation. Approximately 32 million cases of irritable bowel ... Read More
-
WHIM Syndrome - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights WHIM syndrome is a rare genetic disorder caused by CXCR4 mutations, leading to immunodeficiency, warts, hypogammaglobulinemia, and myelokathexis. In 2023, the diagnosed prevalent population in the 7MM was estimated to be around 179 individuals. WHIM is a significant health issue in th ... Read More
-
Post-Bariatric Hypoglycemia - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the United States accounted for approximately 90% of the total Post-Bariatric hypoglycemia market size within the seven major markets. Post-Bariatric hypoglycemia is the development of hypoglycemia (low blood sugar) following bariatric surgery, such as gastric bypass or sleev ... Read More
-
11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor - Pipeline Insight, 2025
DelveInsight’s, “11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor - Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 6+ pipeline drugs in 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor pipeline landscape. It covers the pipeline drug profiles, inc ... Read More
-
1,3-Beta-Glucan Synthase Inhibitor - Pipeline Insight, 2025
“1,3-Beta-Glucan Synthase Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 1,3-Beta-Glucan Synthase Inhibitor development. The report provides detailed coverage of the pipeli ... Read More
-
5-HT1B Agonists - Pipeline Insight, 2025
DelveInsight’s, “5-HT1B Agonists - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in 5-HT1B Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics ... Read More
-
5-HT4 Agonist - Pipeline Insight, 2025
“5-HT4 Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT4 Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, ... Read More
-
Adenosine A1 Receptor Agonist - Pipeline Insight, 2025
“Adenosine A1 Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A1 Receptor Agonist development. The report provides detailed coverage of the pipeline landsca ... Read More
-
Adenosine A3 Receptor Antagonist - Pipeline Insight, 2025
“Adenosine A3 Receptor Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A3 Receptor Antagonist development. The report provides detailed coverage of the pipeline l ... Read More
-
Adenosine A2A Receptor Antagonist - Pipeline Insight, 2025
“Adenosine A2A Receptor Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A2A Receptor Antagonist development. The report provides detailed coverage of the pipeline ... Read More
-
Alpha Receptor Antagonist - Pipeline Insight, 2025
“Alpha Receptor Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha Receptor Antagonist development. The report provides detailed coverage of the pipeline landscape for t ... Read More
-
Alpha-2 Antagonist - Pipeline Insight, 2025
“Alpha-2 Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha-2 Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism ... Read More
-
Amyloid Protein Blockers - Pipeline Insight, 2025
“Amyloid Protein Blockers - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Amyloid Protein Blockers development. The report provides detailed coverage of the pipeline landscape for thi ... Read More
-
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2025
DelveInsight’s, “Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2025” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 pipeline landscape. It covers the pipeline drug profiles ... Read More
-
Angiopoietin Inhibitor - Pipeline Insight, 2025
“Angiopoietin Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Angiopoietin Inhibitor development. The report provides detailed coverage of the pipeline landscape for this me ... Read More
-
Anti GM-CSF Antibody - Pipeline Insight, 2025
“Anti GM-CSF Antibody - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti GM-CSF Antibody development. The report provides detailed coverage of the pipeline landscape for this mechan ... Read More
-
Anti-CD28 Antibody - Pipeline Insight, 2025
“Anti-CD28 Antibody - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD28 Antibody development. The report provides detailed coverage of the pipeline landscape for this mechanism ... Read More
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook